Profarma Distribuidora de Produtos Farmacêuticos Past Earnings Performance
Past criteria checks 5/6
Profarma Distribuidora de Produtos Farmacêuticos has been growing earnings at an average annual rate of 21.6%, while the Healthcare industry saw earnings growing at 21.6% annually. Revenues have been growing at an average rate of 14.5% per year. Profarma Distribuidora de Produtos Farmacêuticos's return on equity is 7.3%, and it has net margins of 1.1%.
Key information
21.6%
Earnings growth rate
21.6%
EPS growth rate
| Healthcare Industry Growth | 11.6% |
| Revenue growth rate | 14.5% |
| Return on equity | 7.3% |
| Net Margin | 1.1% |
| Next Earnings Update | 12 Mar 2025 |
Recent past performance updates
Recent updates
Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Has A Somewhat Strained Balance Sheet
Dec 19
Returns On Capital Are Showing Encouraging Signs At Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3)
Nov 02Shareholders Will Be Pleased With The Quality of Profarma Distribuidora de Produtos Farmacêuticos' (BVMF:PFRM3) Earnings
Aug 14Profarma Distribuidora de Produtos Farmacêuticos S.A.'s (BVMF:PFRM3) 28% Price Boost Is Out Of Tune With Earnings
Mar 01These 4 Measures Indicate That Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Is Using Debt Extensively
Feb 21Returns On Capital Are Showing Encouraging Signs At Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3)
Nov 04Investors Will Want Profarma Distribuidora de Produtos Farmacêuticos' (BVMF:PFRM3) Growth In ROCE To Persist
Aug 03These 4 Measures Indicate That Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Is Using Debt Extensively
Jun 08These 4 Measures Indicate That Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Is Using Debt Extensively
Sep 26Profarma Distribuidora de Produtos Farmacêuticos S.A. (BVMF:PFRM3) Shares Fly 26% But Investors Aren't Buying For Growth
Jan 01Here's Why Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Is Weighed Down By Its Debt Load
May 28Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Might Have The Makings Of A Multi-Bagger
May 07How Much Of Profarma Distribuidora de Produtos Farmacêuticos S.A. (BVMF:PFRM3) Do Institutions Own?
Mar 10Are Profarma Distribuidora de Produtos Farmacêuticos' (BVMF:PFRM3) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Feb 02
Is Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Using Too Much Debt?
Jan 05What Type Of Shareholders Make Up Profarma Distribuidora de Produtos Farmacêuticos S.A.'s (BVMF:PFRM3) Share Registry?
Dec 10Revenue & Expenses Breakdown
How Profarma Distribuidora de Produtos Farmacêuticos makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 9,345 | 107 | 1,158 | 0 |
| 30 Jun 24 | 9,038 | 91 | 1,111 | 0 |
| 31 Mar 24 | 8,889 | 77 | 1,076 | 0 |
| 31 Dec 23 | 8,662 | 70 | 1,046 | 0 |
| 30 Sep 23 | 8,550 | 47 | 1,123 | 0 |
| 30 Jun 23 | 8,291 | 31 | 1,053 | 0 |
| 31 Mar 23 | 8,087 | 82 | 988 | 0 |
| 31 Dec 22 | 7,816 | 81 | 917 | 0 |
| 30 Sep 22 | 7,435 | 87 | 754 | 0 |
| 30 Jun 22 | 7,031 | 96 | 730 | 0 |
| 31 Mar 22 | 6,661 | 63 | 691 | 0 |
| 31 Dec 21 | 6,413 | 78 | 667 | 0 |
| 30 Sep 21 | 6,199 | 95 | 644 | 0 |
| 30 Jun 21 | 5,891 | 99 | 608 | 0 |
| 31 Mar 21 | 5,579 | 60 | 580 | 0 |
| 31 Dec 20 | 5,481 | 52 | 568 | 0 |
| 30 Sep 20 | 5,281 | 44 | 554 | 0 |
| 30 Jun 20 | 5,218 | 16 | 561 | 0 |
| 31 Mar 20 | 5,104 | 21 | 568 | 0 |
| 31 Dec 19 | 4,801 | 12 | 555 | 0 |
| 30 Sep 19 | 4,677 | -5 | 568 | 0 |
| 30 Jun 19 | 4,513 | -13 | 581 | 0 |
| 31 Mar 19 | 4,388 | -12 | 590 | 0 |
| 31 Dec 18 | 4,271 | -10 | 606 | 0 |
| 30 Sep 18 | 4,066 | -37 | 611 | 0 |
| 30 Jun 18 | 4,009 | -65 | 615 | 0 |
| 31 Mar 18 | 4,046 | -91 | 636 | 0 |
| 31 Dec 17 | 4,101 | -113 | 653 | 0 |
| 30 Sep 17 | 4,223 | -126 | 648 | 0 |
| 30 Jun 17 | 4,195 | -100 | 611 | 0 |
| 31 Mar 17 | 4,149 | -67 | 561 | 0 |
| 31 Dec 16 | 4,085 | -49 | 505 | 0 |
| 30 Sep 16 | 3,858 | -18 | 445 | 0 |
| 30 Jun 16 | 3,780 | -14 | 415 | 0 |
| 31 Mar 16 | 3,619 | -23 | 387 | 0 |
| 31 Dec 15 | 3,465 | -21 | 358 | 0 |
| 30 Sep 15 | 3,471 | -34 | 355 | 0 |
| 30 Jun 15 | 3,392 | -48 | 348 | 0 |
| 31 Mar 15 | 3,430 | -46 | 353 | 0 |
| 31 Dec 14 | 3,449 | -52 | 364 | 0 |
| 30 Sep 14 | 3,439 | -37 | 379 | 0 |
| 30 Jun 14 | 3,455 | -11 | 370 | 0 |
| 31 Mar 14 | 3,456 | 0 | 353 | 0 |
| 31 Dec 13 | 3,470 | 20 | 333 | 0 |
Quality Earnings: PFRM3 has high quality earnings.
Growing Profit Margin: PFRM3's current net profit margins (1.1%) are higher than last year (0.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PFRM3 has become profitable over the past 5 years, growing earnings by 21.6% per year.
Accelerating Growth: PFRM3's earnings growth over the past year (130.8%) exceeds its 5-year average (21.6% per year).
Earnings vs Industry: PFRM3 earnings growth over the past year (130.8%) exceeded the Healthcare industry 64.3%.
Return on Equity
High ROE: PFRM3's Return on Equity (7.3%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 15:57 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Profarma Distribuidora de Produtos Farmacêuticos S.A. is covered by 12 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Diego Moreno | BofA Global Research |
| Guilherme Assis | Brasil Plural |
| Joao dos Santos | BTG Pactual |